IL159217A0 - An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine - Google Patents

An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine

Info

Publication number
IL159217A0
IL159217A0 IL15921702A IL15921702A IL159217A0 IL 159217 A0 IL159217 A0 IL 159217A0 IL 15921702 A IL15921702 A IL 15921702A IL 15921702 A IL15921702 A IL 15921702A IL 159217 A0 IL159217 A0 IL 159217A0
Authority
IL
Israel
Prior art keywords
medicine
manufacture
active ingredient
pharmaceutical formulation
pharmaceutically active
Prior art date
Application number
IL15921702A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL159217A0 publication Critical patent/IL159217A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15921702A 2001-06-21 2002-06-19 An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine IL159217A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation
PCT/SE2002/001217 WO2003000293A1 (en) 2001-06-21 2002-06-19 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IL159217A0 true IL159217A0 (en) 2004-06-01

Family

ID=27354711

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15921702A IL159217A0 (en) 2001-06-21 2002-06-19 An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
IL159217A IL159217A (en) 2001-06-21 2003-12-07 Oral pharmaceutical formulation containing a basic active pharmaceutical ingredient with pH-dependent solubility, process for its production and use in medicine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159217A IL159217A (en) 2001-06-21 2003-12-07 Oral pharmaceutical formulation containing a basic active pharmaceutical ingredient with pH-dependent solubility, process for its production and use in medicine

Country Status (31)

Country Link
US (1) US7700582B2 (hu)
EP (1) EP1401502B1 (hu)
JP (1) JP2005501024A (hu)
KR (1) KR20040011542A (hu)
CN (1) CN1518462A (hu)
AR (1) AR034517A1 (hu)
AT (1) ATE314093T1 (hu)
AU (1) AU2002345463B2 (hu)
BG (1) BG108516A (hu)
BR (1) BR0210489A (hu)
CA (1) CA2450449A1 (hu)
CO (1) CO5550466A2 (hu)
CZ (1) CZ299859B6 (hu)
DE (1) DE60208369T2 (hu)
DK (1) DK1401502T3 (hu)
EE (1) EE200400028A (hu)
ES (1) ES2254699T3 (hu)
HU (1) HUP0400850A3 (hu)
IL (2) IL159217A0 (hu)
IS (1) IS2347B (hu)
MX (1) MXPA03011546A (hu)
MY (1) MY130332A (hu)
NO (1) NO20035627D0 (hu)
NZ (1) NZ530086A (hu)
PL (1) PL366432A1 (hu)
RU (1) RU2323006C2 (hu)
SI (1) SI1401502T1 (hu)
SK (1) SK286238B6 (hu)
UA (1) UA77959C2 (hu)
WO (1) WO2003000293A1 (hu)
ZA (1) ZA200309316B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR101016619B1 (ko) * 2001-11-13 2011-02-23 아스텔라스세이야쿠 가부시키가이샤 용해성 약물 지속 방출 시스템
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2584469A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
CL2008000279A1 (es) * 2007-02-01 2008-08-18 Takeda Pharmaceutical Composicion farmaceutica solida que comprende una parte que comprende 2-((6-(3r)-3-amino-1-piperidinil)3,4-dihidro-3-metil-2,4-dioxo-1-(2h)-pirimidin)metil)benzonitrilo, azucar o alcohol de azucar y una segunda parte que comprende pioglitazona y azuc
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DK2262486T3 (da) 2008-08-01 2013-03-25 Krka Tovarna Zdravil D D Novo Mesto Quetiapin sammensætning
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (hu) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5760235A (en) 1992-03-04 1998-06-02 Gyogyszerkutato Intezet Kft. Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof
TW223629B (hu) 1992-03-06 1994-05-11 Hoffmann La Roche
US5783563A (en) 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
BR9607582A (pt) 1995-02-17 1998-07-07 Basf Ag Composto e peptídeo ou substância peptidomimética
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
CA2258915A1 (en) 1996-06-25 1997-12-31 Michael Robert Wiley Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
ATE363292T1 (de) * 1998-09-04 2007-06-15 Scios Inc Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
IL143987A (en) 1999-01-13 2005-12-18 Astrazeneca Ab Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
NO20035627D0 (no) 2003-12-15
AU2002345463B2 (en) 2007-08-30
SK15912003A3 (sk) 2004-05-04
AR034517A1 (es) 2004-02-25
RU2323006C2 (ru) 2008-04-27
EE200400028A (et) 2004-04-15
BG108516A (en) 2004-12-30
DE60208369D1 (de) 2006-02-02
HUP0400850A3 (en) 2010-10-28
ZA200309316B (en) 2005-02-28
RU2003136155A (ru) 2005-05-20
CO5550466A2 (es) 2005-08-31
IS2347B (is) 2008-03-15
CZ20033491A3 (en) 2004-03-17
ES2254699T3 (es) 2006-06-16
CN1518462A (zh) 2004-08-04
CA2450449A1 (en) 2003-01-03
UA77959C2 (en) 2007-02-15
CZ299859B6 (cs) 2008-12-17
EP1401502A1 (en) 2004-03-31
MXPA03011546A (es) 2004-03-19
DE60208369T2 (de) 2006-08-24
ATE314093T1 (de) 2006-01-15
EP1401502B1 (en) 2005-12-28
DK1401502T3 (da) 2006-04-10
US20040242536A1 (en) 2004-12-02
NZ530086A (en) 2005-09-30
BR0210489A (pt) 2004-06-22
SI1401502T1 (sl) 2006-06-30
HUP0400850A2 (hu) 2004-08-30
SK286238B6 (sk) 2008-06-06
MY130332A (en) 2007-06-29
IL159217A (en) 2009-02-11
IS7081A (is) 2003-12-16
JP2005501024A (ja) 2005-01-13
US7700582B2 (en) 2010-04-20
WO2003000293A1 (en) 2003-01-03
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
IL157477A0 (en) Pharmaceutical salts comprising a pharmaceutically active substance and a sugar substitute
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
HUP0500846A2 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
CA2360248A1 (en) Combinations of formoterol and a tiotropium salt
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
IL153167A0 (en) Phenyl derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
HUP0500958A2 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
HUP0303597A3 (en) Diposable vaginal cannula for the simultaneous administration of drugs in different forms
IL162385A (en) Benzothiazole - and benzoxazole - 4,7 - dione derivatives, uses thereof for the preparation of a medicament, medicaments containing them and pharmaceutical compositions containing them
IL162101A (en) Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed